Skip to Main content Skip to Navigation
New interface
Journal articles

Vaccin grippal haute dose : un vaccin adapté aux 65 ans et plus

Abstract : Key points In its report issued in 2016, the French High Council of Public Health (Haut Conseil de la Santé Publique), points out the need for a more effective influenza vaccine for people aged 65 and older, in addition to the need for increasing influenza vaccination coverage rates. A large randomized controlled trial confirmed by real-world studies conducted over 10 influenza seasons demonstrated that switching from 15 to 60 μg HA/strain in the vaccine composition increases protection consistently in people aged 65 years and older, including institutionalized individuals, irrespective of antigenic match or circulating strain. As compared with a standard-dose influenza vaccine (SD), the increased-dose vaccine so-called high dose (HD) protects about a quarter more individuals aged 65 years and older against influenza; beyond flu protection, the high-dose vaccine reduces notably the number of hospital admissions for pneumonia (around 30%) and for cardiorespiratory events (around 20%) in comparison with SD vaccine. Although more reactogenic than the SD vaccines currently used in France, this vaccine meets the usual safety standards for vaccines and while more than 166 million doses have been distributed worldwide, no safety signal has been identified. The high dose quadrivalent influenza vaccine is now licensed in Europe; it is available and reimbursed in France for people aged 65 years and over. It represents a new tool in the vaccination strategy of people aged 65 years and over, and ultimately in the general process of improving prevention of seasonal influenza.
Mots-clés : Grippe Vaccin Seniors
Document type :
Journal articles
Complete list of metadata
Contributor : SCD EHESP Connect in order to contact the contributor
Submitted on : Wednesday, October 19, 2022 - 9:33:41 AM
Last modification on : Thursday, October 20, 2022 - 3:59:49 AM



Gaëtan Gavazzi, Anne Mosnier, Pascal Crepey, Jacques Gaillat. Vaccin grippal haute dose : un vaccin adapté aux 65 ans et plus. La Presse Médicale Formation, 2022, 3 (2), pp.105-118. ⟨10.1016/j.lpmfor.2022.01.001⟩. ⟨hal-03820469⟩



Record views